Literature DB >> 25316813

Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.

Yoshitsugu Mitani1, Pulivarthi H Rao2, Sankar N Maity3, Yu-Chen Lee4, Renata Ferrarotto5, Julian C Post1, Lisa Licitra6, Scott M Lippman7, Merrill S Kies5, Randal S Weber8, Carlos Caulin8, Sue-Hwa Lin4, Adel K El-Naggar9.   

Abstract

PURPOSE: To investigate the molecular events associated with the activation of androgen receptor (AR) as a potential therapeutic target in patients with salivary duct carcinoma (SDC). EXPERIMENTAL
DESIGN: Comprehensive molecular and expression analysis of the AR gene in 35 tumor specimens (20 males and 15 females) and cell lines derived from SDC using Western blotting and RT-PCR, FISH analysis, and DNA sequencing was conducted. In vitro and in vivo animal studies were also performed.
RESULTS: AR expression was detected in 70% of the tumors and was mainly nuclear and homogenous in both male and female SDCs, although variable cytoplasmic and/or nuclear localization was also found. We report the identification of ligand-independent AR splice variants, mutations, and extra AR gene copy in primary untreated SDC tumors. In contrast to prostate cancer, no AR gene amplification was observed. In vitro knockdown of AR in a female derived SDC cell line revealed marked growth inhibition in culture and in vivo androgen-independent tumor growth.
CONCLUSIONS: Our study provides new detailed information on the molecular and structural alterations associated with AR gene activation in SDC and sheds more light on the putative functional role of AR in SDC cells. On the basis of these data, we propose that patients with SDC (male and female) can be stratified for hormone-based therapy in future clinical trials. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25316813      PMCID: PMC4268116          DOI: 10.1158/1078-0432.CCR-14-1746

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  60 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer.

Authors:  Masahiro Sasaki; Yuichiro Tanaka; Geetha Perinchery; Abhipsa Dharia; Ioulia Kotcherguina; Sei ichiro Fujimoto; Rajvir Dahiya
Journal:  J Natl Cancer Inst       Date:  2002-03-06       Impact factor: 13.506

3.  Salivary duct carcinoma.

Authors:  R Delgado; F Vuitch; J Albores-Saavedra
Journal:  Cancer       Date:  1993-09-01       Impact factor: 6.860

4.  Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Authors:  Maria Thadani-Mulero; Luigi Portella; Shihua Sun; Matthew Sung; Alexandre Matov; Robert L Vessella; Eva Corey; David M Nanus; Stephen R Plymate; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2014-02-20       Impact factor: 12.701

5.  A and B forms of the androgen receptor are present in human genital skin fibroblasts.

Authors:  C M Wilson; M J McPhaul
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

6.  Androgen receptor gene mutations in human prostate cancer.

Authors:  H Suzuki; N Sato; Y Watabe; M Masai; S Seino; J Shimazaki
Journal:  J Steroid Biochem Mol Biol       Date:  1993-12       Impact factor: 4.292

7.  Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization.

Authors:  G Jenster; H A van der Korput; C van Vroonhoven; T H van der Kwast; J Trapman; A O Brinkmann
Journal:  Mol Endocrinol       Date:  1991-10

Review 8.  Salivary duct carcinoma.

Authors:  V A Murrah; J G Batsakis
Journal:  Ann Otol Rhinol Laryngol       Date:  1994-03       Impact factor: 1.547

9.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer.

Authors:  T Visakorpi; E Hyytinen; P Koivisto; M Tanner; R Keinänen; C Palmberg; A Palotie; T Tammela; J Isola; O P Kallioniemi
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

Review 10.  Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature.

Authors:  L Barnes; U Rao; J Krause; L Contis; A Schwartz; P Scalamogna
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1994-07
View more
  24 in total

1.  Sex disparities in salivary malignancies: Does female sex impact oncological outcome?

Authors:  Ximena Mimica; Marlena McGill; Ashley Hay; Daniella Karassawa Zanoni; Jatin P Shah; Richard J Wong; Alan L Ho; Marc A Cohen; Snehal G Patel; Ian Ganly
Journal:  Oral Oncol       Date:  2019-05-22       Impact factor: 5.337

2.  Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.

Authors:  Martin G Dalin; Alexis Desrichard; Nora Katabi; Vladimir Makarov; Logan A Walsh; Ken-Wing Lee; Qingguo Wang; Joshua Armenia; Lyndsay West; Snjezana Dogan; Lu Wang; Deepa Ramaswami; Alan L Ho; Ian Ganly; David B Solit; Michael F Berger; Nikolaus D Schultz; Jorge S Reis-Filho; Timothy A Chan; Luc G T Morris
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

3.  Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.

Authors:  Richard K Yang; Pei Zhao; Changxue Lu; Jun Luo; Rong Hu
Journal:  Hum Pathol       Date:  2018-09-26       Impact factor: 3.466

4.  Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.

Authors:  Yoshitsugu Mitani; Sue-Hwa Lin; Kristen B Pytynia; Renata Ferrarotto; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2019-11-26       Impact factor: 12.531

5.  Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.

Authors:  Marlen Haderlein; Claudia Scherl; Sabine Semrau; Sebastian Lettmaier; Markus Hecht; Ramona Erber; Heinrich Iro; Rainer Fietkau; Abbas Agaimy
Journal:  Strahlenther Onkol       Date:  2017-08-21       Impact factor: 3.621

6.  Developing androgen receptor targeting for salivary gland cancers.

Authors:  A L Ho
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

7.  The G-Protein-Coupled Receptor ALX/Fpr2 Regulates Adaptive Immune Responses in Mouse Submandibular Glands.

Authors:  Ching-Shuen Wang; Olga J Baker
Journal:  Am J Pathol       Date:  2018-04-22       Impact factor: 4.307

8.  Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.

Authors:  Kyriakos Chatzopoulos; Andrea R Collins; Sotiris Sotiriou; Michael G Keeney; Daniel W Visscher; Michael Rivera; David J Schembri-Wismayer; Jean E Lewis; Patricia T Greipp; William R Sukov; Ashish V Chintakuntlawar; Katharine A Price; Joaquin J Garcia
Journal:  Head Neck Pathol       Date:  2020-04-29

9.  Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.

Authors:  Pierre Saintigny; Yoshitsugu Mitani; Kristen B Pytynia; Renata Ferrarotto; Dianna B Roberts; Randal S Weber; Merrill S Kies; Sankar N Maity; Sue-Hwa Lin; Adel K El-Naggar
Journal:  Cancer       Date:  2018-10-05       Impact factor: 6.860

Review 10.  Molecular Pathology and Biomarkers.

Authors:  Patrick K Ha; Göran Stenman
Journal:  Adv Otorhinolaryngol       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.